Since their accidental introduction into the Great Lakes in mid- to late-1980s, the freshwater zebra mussels, Dreissena polymorpha, have colonized most lakes and waterways across eastern North America. Their rapid spread is partly attributed to their ability to tenaciously attach to hard substrates via an adhesive apparatus called the byssus, resulting in serious environmental and economic impacts. A detailed ultrastructural study of the bysuss revealed a 10 nm adhesive layer at the attachment interface. Distributions of the main adhesive amino acid, 3,4-dihydroxyphenylalanine (DOPA), and its oxidizing (cross-linking) enzyme, catechol oxidase, were determined histochemically. It was found that, upon aging, DOPA levels remained high in the portion of the byssus closest to the interface, consistent with an adhesive role. In contrast, reduced levels of DOPA corresponded well with high levels of catechol oxidase in the load-bearing component of the byssus, presumably forming cross-links and increasing the cohesive strength.

Since their accidental introduction into the Great Lakes in mid- to late-1980s, the freshwater zebra mussels, Dreissena polymorpha, have colonized most lakes and waterways across eastern North America. Their rapid spread is partly attributed to their ability to tenaciously attach to hard substrates via an adhesive apparatus called the byssus, resulting in serious environmental and economic impacts. A detailed ultrastructural study of the bysuss revealed a 10 nm adhesive layer at the attachment interface. Distributions of the main adhesive amino acid, 3,4-dihydroxyphenylalanine (DOPA), and its oxidizing (cross-linking) enzyme, catechol oxidase, were determined histochemically. It was found that, upon aging, DOPA levels remained high in the portion of the byssus closest to the interface, consistent with an adhesive role. In contrast, reduced levels of DOPA corresponded well with high levels of catechol oxidase in the load-bearing component of the byssus, presumably forming cross-links and increasing the cohesive strength.

La stimulation à haute fréquence (SHF) du noyau sous-thalamique (NST) permet de traiter l'ensemble des symptômes moteurs de la maladie de Parkinson (MP), mais aussi d'atténuer l'apparition les dyskinésies L-Dopa induites, grâce notamment à une réduction massive, voire complète, des prises de L-Dopa chez les patients stimulés. Toutefois, les mécanismes in fine qui sous-tendent l'efficacité thérapeutique de la SHF du NST chez l'homme ne sont pas encore élucidés, tout comme les possibles interactions pouvant exister entre les effets induits par la SHF du NST et ceux (synergiques ou non) d'un traitement à la L-DOPA.<br />Notre travail a porté principalement sur l'animal anesthésié, sain ou hémiparkinsonien, traité de manière chronique ou aiguë à la L-Dopa, et soumis ou non à la SHF du NST. Dans une première partie expérimentale, nous avons analysé chez le rat sain les modifications neurochimiques (variations des contenus en glutamate et en GABA mesurées par microdialyse intracérébrale) induites par la SHF du NST sur des structures situées à distance du NST mais impliquées directement ou indirectement dans les circuits moteurs, comme la region Fr3 du cortex moteur, le colliculus supérieur et le noyau ventro-médian du thalamus.Dans une deuxième partie, nous avons essayé de déterminer si la SHF du NST pouvait modifier la réponse à la L-Dopa (suite à un traitement chronique ou aigu) sur les contenus en dopamine (et ses métabolites DOPAC et HVA), en glutamate et en GABA. Les principaux résultats obtenus mettent en exergue une interaction synergique entre les effets d'une injection unique de L-Dopa et ceux induits par la SHF du NST. En effet, il apparaît que cette stimulation stabilise les taux élevés de dopamine suite au traitement L-Dopa, retardant ainsi son métabolisme. Ces résultats pourraient donc apporter de arguments intéressants concernant les effets bénéfiques de la SHF du NST observés chez les malades parkinsoniens, notamment dans la stabilisation des fluctuations motrices. <br />Les données obtenues au cours de ce travail doctoral apportent de nouveaux arguments pour la compréhension des mécanismes de la SHF du NST, et amènent de nouvelles perspectives justifiant l'intérêt thérapeutique de la SHF dans la maladie de Parkinson.

Submitted by Rodrigo Martins Cruz (rodrigo.cruz@ufvjm.edu.br) on 2015-02-19T13:34:45Z No. of bitstreams: 5 fer.pdf: 3531496 bytes, checksum: da51c0e714843d62cd73ad67737d85b2 (MD5) license_url: 52 bytes, checksum: 3d480ae6c91e310daba2020f8787d6f9 (MD5) license_text: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) license_rdf: 23898 bytes, checksum: e363e809996cf46ada20da1accfcd9c7 (MD5) license.txt: 2110 bytes, checksum: b4c884761e4c6c296ab2179d378436d4 (MD5) / Approved for entry into archive by Rodrigo Martins Cruz (rodrigo.cruz@ufvjm.edu.br) on 2015-02-20T10:58:08Z (GMT) No. of bitstreams: 5 fer.pdf: 3531496 bytes, checksum: da51c0e714843d62cd73ad67737d85b2 (MD5) license_url: 52 bytes, checksum: 3d480ae6c91e310daba2020f8787d6f9 (MD5) license_text: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) license_rdf: 23898 bytes, checksum: e363e809996cf46ada20da1accfcd9c7 (MD5) license.txt: 2110 bytes, checksum: b4c884761e4c6c296ab2179d378436d4 (MD5) / Made available in DSpace on 2015-02-20T10:58:09Z (GMT). No. of bitstreams: 5 fer.pdf: 3531496 bytes, checksum: da51c0e714843d62cd73ad67737d85b2 (MD5) license_url: 52 bytes, checksum: 3d480ae6c91e310daba2020f8787d6f9 (MD5) license_text: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) license_rdf: 23898 bytes, checksum: e363e809996cf46ada20da1accfcd9c7 (MD5) license.txt: 2110 bytes, checksum: b4c884761e4c6c296ab2179d378436d4 (MD5) Previous issue date: 2013-02-20 / L-Dopa ? convertida em dopamina no c?rebro e continua a ser a droga mais amplamente prescrita no tratamento da doen?a de Parkinson. Um sens?vel e seletivo sensor foi desenvolvido para a determina??o voltam?trica de L-Dopa em formula??es farmac?uticas usando um Eletrodo de Grafite Pirol?tico de Plano Basal (EGPPB) modificado com cloro(piridil)bis(dimetilglioximato) de cobalto (III) (Co(DMG)2ClPy), um modelo sint?tico da vitamina B12, adsorvido em Nanotubos de Carbono de Paredes M?ltiplas (NCPM), o qual foi denominado EGPPB/NCPM/Co(DMG)2ClPy. Microscopia Eletr?nica de Varredura e Espectroscopia no Infravermelho por Transformada de Fourier foram utilizadas para caracterizar os materiais. A oxida??o de L-Dopa utilizando o EGPPB/NCPM/Co(DMG)2ClPy foi investigada por Voltametria C?clica, Amperometria, Voltametria de Pulso Diferencial e Voltametria de Onda Quadrada. O eletrodo modificado apresentou uma excelente atividade catal?tica para a oxida??o de L-Dopa em 180 mV vs. Ag/AgCl. Os par?metros que influenciam a resposta do eletrodo foram investigados. As condi??es ?timas foram encontradas para o eletrodo modificado com 100 ?mol L-1 de Co(DMG)2ClPy, 2 mg mL-1 de NCPM, em solu??o tamp?o fosfato na concentra??o de 0,2 mol L-1 (pH 7,4). O n?mero de el?trons envolvidos na oxida??o de L-Dopa foi igual a dois. As correntes de pico voltam?tricas apresentaram uma resposta linear para a concentra??o de L-Dopa no intervalo de 3 a 100 ?mol L-1 para n = 12 (R = 0,9992), com sensibilidade, limite de detec??o e limite de quantifica??o iguais a 4,43 ?A cm-2/?mol L-1, 0,86 e 2,87 ?mol L-1, respectivamente. O Desvio Padr?o Relativo para 10 determina??es de solu??o 50 ?mol L-1 de L-Dopa foi de 1,63%. Os resultados obtidos para a determina??o de L-Dopa em formula??es farmac?uticas est?o de acordo com o m?todo de compara??o oficial. Estudos de adi??o e recupera??o do analito foram realizados para avaliar a exatid?o do m?todo e verificou-se que foi poss?vel uma porcentagem de recupera??o entre 99,4 e 101,5% para a L-Dopa. Portanto, o sensor desenvolvido pode ser aplicado com sucesso para a determina??o do referido f?rmaco em medicamentos. / Disserta??o (Mestrado) ? Programa de P?s-Gradua??o em Qu?mica, Universidade Federal dos Vales do Jequitinhonha e Mucuri, 2011. / ABSTRACT L-Dopa is converted to dopamine in the brain and remains the most widely prescribed drug in the treatment of Parkinson's disease. A sensitive and selective method was developed for the voltammetric determination of L-Dopa in pharmaceutical formulations using a Basal Plane Pyrolytic Graphite Electrode (BPPGE) modified with chloro(pyridil)bis(dimethylglyoximato)cobalt(III) (Co(DMG)2ClPy), synthetic model of vitamin B12, absorbed on Multi-walled Carbon Nanotube (MWCNT), denominated MWCNT/Co(DMG)2ClPy/BPPGE. Scanning Electron Microscopy and Fourier Transform Infrared Spectroscopy were used to characterize the materials. The oxidation of L-Dopa using the MWCNT/Co(DMG)2ClPy/BPPGE was investigated by Cyclic Voltammetry, Amperometry, Differential Pulse Voltammetry and Square Wave Voltammetry. The modified electrode showed an excellent catalytic activity for L-Dopa oxidation at 180 mV vs. Ag/AgCl. The parameters that influence on the electrode response were investigated. The optimum conditions were found to the modified electrode with 100 ?mol L-1 Co(DMG)2ClPy, 2 mg mL-1 MWCNT, in 0.2 mol L-1 phosphate buffer solution (pH 7.4). The number of electrons involved in L-Dopa oxidation was two. Voltammetric peak currents showed a linear response for L-Dopa concentration in the range from 3 up to 100 ?mol L-1 for n = 12 (R = 0.9992), with a sensitivity, detection limit and quantification limit of 4.43 ?A cm-2/?mol L-1, 0.86 and 2.87 ?mol L-1, respectively. The Relative Standard Deviation for 10 determinations of 50 ?mol L-1 L-Dopa was 1.63%. The results obtained for L-Dopa determination in pharmaceutical formulations was in accordance with the official method of comparison. Studies of addition and recovery of the analyte were carried out to evaluate the error of the method and was verified a recovery percentage between 99.4 and 101.5% for L-Dopa. Therefore the sensor developed can be applied successfully to the determination of this drug in pharmaceuticals formulations.

The aim of the study was to determine the influence of phenolics content and inoculation with soil extract on microbial respiration, on the phenoloxidase (PhOx), peroxidase (PerOx) and newly Mn-peroxidase (MnP) activity in two dominating litter samples (Calamagrostis villosa and Picea abies) differing in phenolics content from Plešné and Čertovo lake watersheds. At PhOx and PerOx activity, the dependence on incubation temperature with L-DOPA was estimated. PhOx and MnP activities significantly increased with higher content of hardly decomposable phenolics, but decreased with water extractable phenolics content. Inoculation with soil extract had no influence on microbial respiration, enzyme activity, nor on decomposition of phenolics. Microbial respiration was significantly higher at 10°C, but average enzyme activity was comparable at 0 and 10°C. PhOx activities had temperature optimum higher than 22°C, while PerOx activities had temperature optimum at 0 - 15°C.

No description available.

La maladie de Parkinson (MP) est un trouble dégénératif du système nerveux central qui affecte principalement les personnes âgées. Son principal traitement est la L-3,4-dihydroxyphénylalanine (L-DOPA), qui malheureusement provoque des problèmes handicapants tels que les dyskinésies et les psychoses à la suite d’une administration chronique. Peu de traitements sont disponibles pour réduire efficacement ces complications et certains interfèrent avec l’effet thérapeutique de la L-DOPA, alors que d’autres induisent des effets secondaires potentiellement dangereux pour la vie des patients. Il est donc crucial de découvrir de nouvelles cibles thérapeutiques. Des études cliniques et précliniques ont montré que le site de liaison de la glycine du récepteur N-méthyl-D-aspartate (NMDA) est une cible thérapeutique prometteuse pour les problèmes moteurs de la MP. En effet, la stimulation de celui-ci augmenterait la transmission glutamatergique via la voie hyperdirecte des ganglions de la base, et par conséquent favoriserait l’inhibition du thalamus qui mènera à une moindre activation du cortex moteur, et donc possiblement moins de dyskinésies. De plus, puisque l’activation des récepteurs NMDA le long de la voie nigro-striée augmente la libération de dopamine dans le striatum, il est possible qu’un effet antiparkinsonien soit également obtenu. L’objectif de cette étude est de caractériser les potentiels anti-dyskinétique, antipsychotique et antiparkinsonien de l’inhibition sélective du transporteur de la glycine 1 (GlyT1) chez deux modèles animaux de la MP. Le chapitre 1 décrit le développement et la validation d’une nouvelle méthode de détection pour quantifier les niveaux plasmatiques du bitopertin, un inhibiteur du GlyT1. Le chapitre 2 détermine le profil pharmacocinétique du bitopertin chez le rat, à la suite d’une administration sous-cutanée. Le chapitre 3 évalue l’effet du bitopertin sur la dyskinésie et le parkinsonisme chez le rat hémi-parkinsonien, montrant une amélioration significative de la dyskinésie et du parkinsonisme. Le chapitre 4 évalue l’effet de l’ALX-5407, un inhibiteur du GlyT1, sur la dyskinésie et les comportements de types psychotiques chez le ouistiti lésé au 1-méthyl-4-phényl-1,2,3,6-tétrahydropyridine (MPTP), démontrant une amélioration de la sévérité globale de la dyskinésie, des comportements de type psychose et du parkinsonisme. Dans l’ensemble, ces résultats fournissent des données convaincantes pour soutenir le potentiel thérapeutique de l’inhibition de GlyT1. De plus, le bitopertin a fait l’objet d’essais cliniques approfondies pour le traitement de la schizophrénie, et a présenté un profil de sécurité et de tolérance bien documenté, ce qui en fait un candidat attrayant pour une nouvelle étude clinique dans le traitement de la MP. / Parkinson's disease (PD) is a degenerative disorder of the central nervous system that primarily affects older people. Its main treatment is L-3,4-dihydroxyphenylalanine (L-DOPA), which unfortunately causes disabling problems such as dyskinesias and psychosis following chronic administration. Few treatments are available to effectively reduce these complications, and some interfere with the therapeutic effect of L-DOPA, while others induce potentially life-threatening side effects. It is therefore crucial to discover new therapeutic targets. Clinical and preclinical studies have shown that the glycine site of the N-methyl-D-aspartate (NMDA) receptor is a promising therapeutic target for motor problems in PD. Indeed, this may increase glutamatergic transmission via the hyperdirect pathway of the basal ganglia, and consequently promote inhibition of the thalamus, which will lead to minimal activation of the motor cortex, and therefore possibly less dyskinesia. Additionally, since activation of NMDA receptors along the nigrostriatal pathway increases dopamine release in the striatum, it is possible that an antiparkinsonian effect is also achieved. The objective of this study is to characterize the anti-dyskinetic, antipsychotic and antiparkinsonian potentials of selective inhibition of glycine transporter 1 (GlyT1) in two animal models of PD. Chapter 1 describes the development and validation of a new detection method to quantify plasma levels of bitopertin, a GlyT1 inhibitor. Chapter 2 determines the pharmacokinetic profile of bitopertin in rats, following subcutaneous administration. Chapter 3 evaluates the effect of bitopertin on dyskinesia and parkinsonism in hemi-parkinsonian rats, showing a significant improvement in dyskinesia and parkinsonism. Chapter 4 evaluates the effect of ALX-5407, a GlyT1 inhibitor, on dyskinesia and psychotic-like behaviours in marmosets injured with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), demonstrating an improvement in the overall severity of dyskinesia, psychosis-like behaviours, and parkinsonism. Taken together, these results provide compelling data to support the therapeutic potential of GlyT1 inhibition. Additionally, bitopertin has been extensively tested in clinical trials for the treatment of schizophrenia, and has demonstrated a well-documented safety and tolerability profile, making it an attractive candidate for further clinical study in the treatment of the PD.

<p> Exposure to chronic low oxygen (hypoxia) leads to a series of adaptive responses involving changes in gene expression that are critical for cell, tissue, and organismal survival. These changes are mediated by an important set of regulators belonging to the hypoxia inducible factor (HIF) family of transcription factors (e.g. HIF-lα, HIF-2α, HIF3α) which undergo rapid degradation during normal oxygen (normoxia) but are rapidly stabilized during hypoxia. While the role of HIF-1α has been extensively studied in many cell types, there have been relatively few studies on the role of HIF-2α, though recent evidence suggests its function maybe tissue specific. This thesis examined the hypothesis that HIF-2α plays a central role in the development and function of catecholaminergic cells of the sympathoadrenal (SA) lineage. The study was aided by use of an immortalized line of rat adrenomedullary chromaffin cells (i.e. MAH cells), derived from fetal SA progenitors, which express several hypoxia-sensitive properties characteristic of native cells in the adrenal gland. In Chapter 2, I investigated the potential contributions of mitochondrial reactive oxygen species (ROS) and 0 2 consumption to HIF-2α induction in MAH cells exposed to chronic hypoxia (2% O(2); 24 hr). In MAH cells, chronic hypoxia caused an increase in HIF-2α induction which was blocked by inhibition of any of the mitochondrial complexes using pharmacological agents, or by specific inhibition of complexes III and IV using RNAi techniques. It was found that in this 0 2-sensitive chromaffin cell line mitochondrial O(2) consumption, rather than changes in ROS, regulated HIF-2α induction during hypoxia. In Chapter 3, I investigated the hypothesized role of HIF-2α in the development of the catecholaminergic phenotype in cells of the SA lineage using the MAH cell line as a model. Mutant MAH cells, with depleted HIF-2α due to siRNA knock-down, showed dramatically lower levels of dopamine and noradrenaline compared to untransfected and scrambled control cells, regardless of whether the cells were cultured under normoxia or chronic hypoxia. This was correlated with a marked reduction in the expression of DOPA decarboxylase (DDC) and dopamine B hydroxylase (DBH), though the expression of tyrosine hydroxylase (TH) was unaffected. Moreover, HIF-2α was able to bind to a region of the DDC gene promoter which contains two putative hypoxia response elements (HREs). These data suggest that a basal level of HIF-2α function is required for the normal developmental expression of DDC and DBH in SA progenitor cells, and that loss of this function leads to impaired catecholamine (CA) biosynthesis. In Chapter 4, I investigated genes regulated by chronic hypoxia in MAH cells, with a focus on those involved in CA metabolism, storage, and secretion. Using microarray analysis combined with QPCR and RNAi knock-down methodology I uncovered several genes, involved in amine vesicular packaging, trafficking and secretion, which were upregulated during chronic hypoxia. One gene specifically, the adenosine A(2A) receptor (A(2A)R) gene, which appears to modulate CA secretion via autocrine or paracrine actions of extracellular adenosine, was dramatically upregulated in chronic hypoxia. Interestingly, this effect was completely abolished in HIF-2α knockdown MAH cells, suggesting a critical involvement of HIF-2α. Chromatin immunoprecipitation (ChIP) assays revealed that HIF-2α bound to the promoter region of the A(2A)R gene which contains a putative hypoxia response element (HRE) immediately upstream of exon 1. Ratiometric fluorescence measurements of intracellular Ca(2+) revealed that adenosine (50 μM) potentiated the high K(+)-evoked rise in [Ca(2+)]i in MAH cells. This effect of adenosine was further enhanced after chronic hypoxia, but was abolished in HIF-2α knock-down cells. In conclusion, these data suggest that HIF-2α is a key regulator of several genes involved in CA biosynthesis, and of others that mediate the facilitatory effects of chronic hypoxia on CA secretion in sympathoadrenal derivatives. / Thesis / Doctor of Philosophy (PhD)